Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

bluebird bio lodges counterclaim against Spark Therapeutics

Spark previously accused bluebird of misusing trademarks relating to the word ‘spark’ in marketing/educational materials

- PMLiVE

UK to provide genomic sequencing globally to identify COVID-19 variants

Public Health England has identified the first group of countries to receive genomic sequencing support through NVAP

- PMLiVE

FDA grants priority review for AZ, Amgen’s tezepelumab for asthma

Drug 'has the potential to transform treatment for a broad population of severe asthma patients'

- PMLiVE

Pre-launch planning and DSLs – the new ways to create launch excellence in pharma

Looking at the top three goals of pre-launch and the role of digital scientific leaders and social media in launch excellence

- PMLiVE

FDA rejects Provention Bio’s type 1 diabetes prevention drug

FDA said a study of healthy volunteers failed to demonstrate that the planned commercial product is comparable to an older version used in previous clinical trials

- PMLiVE

UK announces new ten-year Life Sciences Vision to support life sciences sector

UK government has launched a £200m life sciences investment programme to support innovative life sciences companies

- PMLiVE

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

Roche's Actemra and Sanofi's Kevzara are included in WHO's updated patient care guidelines

- PMLiVE

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

Multiple myeloma is the second most common blood cancer

- PMLiVE

Pharma’s authentic proof of purpose influences decisions among HCPs and payers

By Ludivine Delattre and Stacy Vaughn

- PMLiVE

Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant

Data suggests vaccine is 64% effective at preventing infection caused by Delta variant after two doses

- PMLiVE

Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial

HER-Vaxx plus chemotherapy resulted in ORR of 50% compared to 29% for chemotherapy alone

- PMLiVE

MHRA outlines two-year delivery plan with ‘patient first’ focus

New delivery plan also outlines strategy for UK regulatory body following Brexit

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links